Switch theme
Sign up to access all valuation multiples
Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1204 - Atopic Dermatitis, and BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is Derived from Australia.
1984
3
LTM Revenue $8.8M
LTM EBITDA -$25.5M
$379M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Botanix Pharmaceuticals has a last 12-month revenue of $8.8M and a last 12-month EBITDA of -$25.5M.
In the most recent fiscal year, Botanix Pharmaceuticals achieved revenue of $0.4M and an EBITDA of -$8.7M.
Botanix Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Botanix Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.1M | $0.4M | XXX | XXX | XXX |
| Gross Profit | n/a | $0.1M | XXX | XXX | XXX |
| Gross Margin | NaN% | 17% | XXX | XXX | XXX |
| EBITDA | -$5.6M | -$8.7M | XXX | XXX | XXX |
| EBITDA Margin | -8706% | -2291% | XXX | XXX | XXX |
| Net Profit | -$8.3M | -$5.8M | XXX | XXX | XXX |
| Net Margin | -12795% | -1521% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Botanix Pharmaceuticals's stock price is AUD 0 (or $0).
Botanix Pharmaceuticals has current market cap of AUD 651M (or $409M), and EV of AUD 603M (or $379M).
See Botanix Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $379M | $409M | XXX | XXX | XXX | XXX | $-0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Botanix Pharmaceuticals has market cap of $409M and EV of $379M.
Botanix Pharmaceuticals's trades at 43.0x LTM EV/Revenue multiple, and -14.9x LTM EBITDA.
Analysts estimate Botanix Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Botanix Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $379M | XXX | XXX | XXX |
| EV/Revenue | 66.4x | XXX | XXX | XXX |
| EV/EBITDA | -19.7x | XXX | XXX | XXX |
| P/E | -21.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -17.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBotanix Pharmaceuticals's NTM/LTM revenue growth is 618%
Botanix Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $3.4M for the same period.
Over next 12 months, Botanix Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Botanix Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Botanix Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 485% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -338% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 54% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 280% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $3.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 55% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1105% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 301% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 2669% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Botanix Pharmaceuticals acquired XXX companies to date.
Last acquisition by Botanix Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Botanix Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Botanix Pharmaceuticals founded? | Botanix Pharmaceuticals was founded in 1984. |
| Where is Botanix Pharmaceuticals headquartered? | Botanix Pharmaceuticals is headquartered in Australia. |
| How many employees does Botanix Pharmaceuticals have? | As of today, Botanix Pharmaceuticals has 3 employees. |
| Is Botanix Pharmaceuticals publicy listed? | Yes, Botanix Pharmaceuticals is a public company listed on ASX. |
| What is the stock symbol of Botanix Pharmaceuticals? | Botanix Pharmaceuticals trades under BOT ticker. |
| When did Botanix Pharmaceuticals go public? | Botanix Pharmaceuticals went public in 1985. |
| Who are competitors of Botanix Pharmaceuticals? | Similar companies to Botanix Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Botanix Pharmaceuticals? | Botanix Pharmaceuticals's current market cap is $409M |
| What is the current revenue of Botanix Pharmaceuticals? | Botanix Pharmaceuticals's last 12-month revenue is $8.8M. |
| What is the current EBITDA of Botanix Pharmaceuticals? | Botanix Pharmaceuticals's last 12-month EBITDA is -$25.5M. |
| What is the current EV/Revenue multiple of Botanix Pharmaceuticals? | Current revenue multiple of Botanix Pharmaceuticals is 43.0x. |
| What is the current EV/EBITDA multiple of Botanix Pharmaceuticals? | Current EBITDA multiple of Botanix Pharmaceuticals is -14.9x. |
| What is the current revenue growth of Botanix Pharmaceuticals? | Botanix Pharmaceuticals revenue growth between 2023 and 2024 was 485%. |
| Is Botanix Pharmaceuticals profitable? | Yes, Botanix Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
